@prefix : <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix opv: <http://inab.certh.gr/OpenPVSignal> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix openpvsignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl> .
@base <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl> .

<http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl> rdf:type owl:Ontology ;
                                                                         owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ,
                                                                                     mp: ;
                                                                         rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/277447/"^^xsd:anyURI ;
                                                                         rdfs:label "Ceftriaxone and Hepatitis in Patients 75 Years and Older"^^rdfs:Literal ;
                                                                         owl:versionInfo "draft-v0.95-20211007"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


###  http://purl.org/mp/supportedBy
mp:supportedBy rdf:type owl:ObjectProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ALT_increased
:ALT_increased rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R74.0" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10001845 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "ALT increased" ;
               rdfs:label "ALT increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#AST_increased
:AST_increased rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R74.0" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10003544 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "AST increased" ;
               rdfs:label "AST increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Acenocoumarol
:Acenocoumarol rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AA07" ;
               rdfs:label "Acenocoumarol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Acepromazine
:Acepromazine rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AA04" ,
                                                                           "N05BA" ;
              rdfs:label "Acepromazine / aceprometazine / clorazepic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Acetaminophen
:Acetaminophen rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02BE01" ,
                                                                            "N02BE51" ,
                                                                            "N02BE71" ;
               rdfs:label "Acetaminophen" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Acetylcysteine
:Acetylcysteine rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R05CB01" ,
                                                                             "S01XA08" ,
                                                                             "V03AB23" ;
                rdfs:label "Acetylcysteine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#AcetylsalicylicAcid
:AcetylsalicylicAcid rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A01AD05" ,
                                                                                  "B01AC06" ,
                                                                                  "B01AC56" ,
                                                                                  "C10BX01" ,
                                                                                  "C10BX02" ,
                                                                                  "C10BX04" ,
                                                                                  "C10BX05" ,
                                                                                  "C10BX06" ,
                                                                                  "C10BX08" ,
                                                                                  "M01BA03" ,
                                                                                  "N02BA01" ,
                                                                                  "N02BA51" ,
                                                                                  "N02BA71" ;
                     rdfs:label "Acetylsalicylic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Allopurinol
:Allopurinol rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M04AA01" ,
                                                                          "M04AA51" ;
             rdfs:label "Allopurinol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Alprazolam
:Alprazolam rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA12" ;
            rdfs:label "Alprazolam" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ambroxol
:Ambroxol rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R05CB06" ;
          rdfs:label "Ambroxol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Amikacin
:Amikacin rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01GB06" ;
          rdfs:label "Amikacin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Amineptine
:Amineptine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AA19" ;
            rdfs:label "Amineptine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Amiodarone
:Amiodarone rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01BD01" ;
            rdfs:label "Amiodarone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Amoxicillin
:Amoxicillin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BD01" ,
                                                                          "A02BD03" ,
                                                                          "A02BD04" ,
                                                                          "A02BD05" ,
                                                                          "A02BD06" ,
                                                                          "A02BD07" ,
                                                                          "A02BD10" ,
                                                                          "A02BD11" ,
                                                                          "J01CA04" ,
                                                                          "J01CR02" ,
                                                                          "J01CR50" ;
             rdfs:label "Amoxicillin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#AnabolicSteroids
:AnabolicSteroids rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A14A" ;
                  rdfs:label "Anabolic steroids" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Antiseizure_medication
:Antiseizure_medication rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03" ;
                        rdfs:label "Antiseizure medication" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Apixaban
:Apixaban rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AF02" ;
          rdfs:label "Apixaban" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Atorvastatin
:Atorvastatin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA05" ,
                                                                           "C10BA05" ,
                                                                           "C10BX03" ,
                                                                           "C10BX06" ,
                                                                           "C10BX08" ,
                                                                           "C10BX11" ;
              rdfs:label "Atorvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Bell_report
:Bell_report rdf:type owl:NamedIndividual ,
                      <http://purl.obolibrary.org/obo/OAE_0001197> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatic_enzymes_increased ,
                                                                                      :Hepatitis ,
                                                                                      :haemolytic_anaemia ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
             mp:references :Ref.6 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Bell and co-workers described an adolescent who experienced acute haemolytic anaemia and severe hepatitis after four days of ceftriaxone therapy. All hepatic enzymes increased dramatically to levels over 20,000 IU/L and the outcome was fatal.6" ;
             rdfs:label "Bell report" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Bisoprolol
:Bisoprolol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AB07" ,
                                                                         "C07AB57" ,
                                                                         "C07BB07" ,
                                                                         "C07FB07" ,
                                                                         "C09BX02" ;
            rdfs:label "Bisoprolol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Bromazepam
:Bromazepam rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA08" ;
            rdfs:label "Bromazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Buflomedil
:Buflomedil rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C04AX20" ;
            rdfs:label "Buflomedil" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Bumetanide
:Bumetanide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA02" ,
                                                                         "C03CB02" ,
                                                                         "C03EB02" ,
                                                                         "G01AE10" ;
            rdfs:label "Bumetanide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Candesartan
:Candesartan rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09CA06" ;
             rdfs:label "Candesartan" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Carbimazole
:Carbimazole rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "H03BB01" ;
             rdfs:label "Carbimazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Carbocisteine
:Carbocisteine rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R05CB03" ;
               rdfs:label "Carbocisteine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Cefotaxime
:Cefotaxime rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01DD01" ,
                                                                         "J01DD51" ;
            rdfs:label "Cefotaxime" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ceftriaxone
:Ceftriaxone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Ceftriaxone_triggering_hepatitis_mechanism ,
                                                                           :Mechanism_of_ceftriaxone ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01DD04" ,
                                                                          "J01DD54" ,
                                                                          "J01DD63" ;
             rdfs:label "Ceftriaxone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ceftriaxone_and_Hepatitis_in_Patients_75_Years_and_Older
:Ceftriaxone_and_Hepatitis_in_Patients_75_Years_and_Older rdf:type owl:NamedIndividual ,
                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Pharmacovigilance_Signal_Report> ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_author> :Dr_Ian_Boyd ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_signal> :pvSignal ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "01/12/2018"^^xsd:date ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_overall_conclusion> "causal association" ;
                                                          rdfs:label "Ceftriaxone and Hepatitis in Patients 75 Years and Older" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ceftriaxone_labelling
:Ceftriaxone_labelling rdf:type owl:NamedIndividual ,
                                <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_part_of> :Literature_and_Labelling ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatic_enzymes_increased ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                       mp:references :Ref.1 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "As stated above, the product information for ceftriaxone notes that hepatic enzymes increased is reported as one of the most frequently reported adverse reactions.1" ,
                                                                                   "The product literature does not refer to hepatitis. Currently, the only hepatic reaction mentioned in the adverse drug reaction section of the product labels is hepatic enzymes increased which is reported as one of the most frequently reported adverse reactions" ;
                       rdfs:label "Ceftriaxone labelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ceftriaxone_triggering_hepatitis_mechanism
:Ceftriaxone_triggering_hepatitis_mechanism rdf:type owl:NamedIndividual ,
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_potential_confounding_factor> :Older_age ,
                                                                                                                             :Reduced_renal_function ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                                                     :hepatotoxicity ;
                                            mp:references :Ref.1 ,
                                                          :Ref.17 ,
                                                          :Ref.18 ,
                                                          :Ref.19 ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "On the basis of other liver reactions reported, however, such as cholestasis and jaundice, cholestatic hepatitis may be more common in association with ceftriaxone. It is interesting to speculate on the possibility of a mechanism to explain why patients 75 years and older may be susceptible to this association. Renal clearance of ceftriaxone is 5 - 12 ml/min with 50 - 60% of ceftriaxone excreted unchanged in the urine, primarily by glomerular filtration, while 40 - 50% is excreted unchanged in the bile. The elimination half-life of total ceftriaxone in adults is about 8 hours. The product information notes that in patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone provided hepatic function is not impaired. Only in cases of preterminal renal failure (creatinine clearance < 10 ml/min) should the ceftriaxone dosage not exceed 2 g daily. However, the product information also states that in older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.1 Adverse drug reactions are well known as a major problem in the elderly population and reduced renal function is an important reason.17 It is possible that the prolonged clearance in elderly patients may result in such patients being exposed to ceftriaxone for a longer period of time and a resulting increased risk of hepatotoxicity. It is noteworthy that increasing age is a risk factor for the development of hepatotoxicity in association with two penicillin antibiotics.18,19" ;
                                            rdfs:label "Ceftriaxone triggering hepatitis mechanism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Cefuroxime
:Cefuroxime rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01DC02" ,
                                                                         "J01RA03" ,
                                                                         "S01AA27" ;
            rdfs:label "Cefuroxime" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Cephalosporins
:Cephalosporins rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01D" ;
                rdfs:label "Cephalosporins" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Chlorpromazine
:Chlorpromazine rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AA01" ;
                rdfs:label "Chlorpromazine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Chlortalidone
:Chlortalidone rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03BA04" ;
               rdfs:label "Chlortalidone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Cholestasis
:Cholestasis rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K831" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10008635 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cholestasis" ;
             rdfs:label "Cholestasis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Cholestatic_hepatitis
:Cholestatic_hepatitis rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10008639 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cholestatic hepatitis" ;
                       rdfs:label "Cholestatic hepatitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ciprofloxacin
:Ciprofloxacin rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01MA02" ,
                                                                            "J01RA10" ,
                                                                            "J01RA11" ,
                                                                            "J01RA12" ,
                                                                            "S01AE03" ,
                                                                            "S02AA15" ,
                                                                            "S03AA07" ;
               rdfs:label "Ciprofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Clarithromycin
:Clarithromycin rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BD04" ,
                                                                             "A02BD05" ,
                                                                             "A02BD06" ,
                                                                             "A02BD07" ,
                                                                             "A02BD09" ,
                                                                             "A02BD11" ,
                                                                             "J01FA09" ;
                rdfs:label "Clarithromycin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Clindamycin
:Clindamycin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D10AF01" ,
                                                                          "D10AF51" ,
                                                                          "G01AA10" ,
                                                                          "J01FF01" ;
             rdfs:label "Clindamycin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Clobazam
:Clobazam rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "‎N05BA09‎" ;
          rdfs:label "Clobazam" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Clopidogrel
:Clopidogrel rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AC04" ;
             rdfs:label "Clopidogrel" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Clorazepic_acid
:Clorazepic_acid rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA05" ;
                 rdfs:label "Clorazepic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Clostridium_difficile-associated_diarrhea
:Clostridium_difficile-associated_diarrhea rdf:type owl:NamedIndividual ,
                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012734 ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Diarrhea, Clostridium difficile" ;
                                           rdfs:label "Clostridium difficile-associated diarrhea" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Cloxacillin
:Cloxacillin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01CF01" ,
                                                                          "J01CF02" ,
                                                                          "J01CF05" ;
             rdfs:label "Cloxacillin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Clozapine
:Clozapine rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AH02" ;
           rdfs:label "Clozapine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Colecalciferol
:Colecalciferol rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M05BB03" ;
                rdfs:label "Colecalciferol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Cyproterone
:Cyproterone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G03HB01" ;
             rdfs:label "Cyproterone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Dalteparin
:Dalteparin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AB04" ;
            rdfs:label "Dalteparin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Danazol
:Danazol rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G03XA01" ;
         rdfs:label "Danazol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Digoxin
:Digoxin rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01AA05" ;
         rdfs:label "Digoxin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Diltiazem
:Diltiazem rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C05AE03" ,
                                                                        "C08DB01" ;
           rdfs:label "Diltiazem" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Dipyridamole
:Dipyridamole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AC07" ;
              rdfs:label "Dipyridamole" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Discussion_and_Conclusion
:Discussion_and_Conclusion rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Conclusion> ;
                           mp:references :Ref.1 ,
                                         :Ref.10 ,
                                         :Ref.11 ,
                                         :Ref.12 ,
                                         :Ref.13 ,
                                         :Ref.14 ,
                                         :Ref.15 ,
                                         :Ref.16 ,
                                         :Ref.17 ,
                                         :Ref.18 ,
                                         :Ref.19 ,
                                         :Ref.3 ,
                                         :Ref.4 ,
                                         :Ref.5 ,
                                         :Ref.6 ,
                                         :Ref.7 ,
                                         :Ref.9 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Case reports in VigiBase suggest that there is a signal for the association of ceftriaxone and hepatitis in patients 75 years and older. Ceftriaxone was the only drug suspected in 27 of the 67 cases. In the remaining 40 cases, one other drug was suspected in 16 cases and from three to five other drugs suspected in the remaining 24 cases. A detailed analysis of the respective causalities of all suspected drugs in each of the cases is beyond the scope of this assessment. However, of the suspected drugs which occur most in multiple cases, hepatotoxicity is mentioned as an adverse reaction in the product information for metronidazole, amoxicillin/clavulanic acid, ciprofloxacin, ofloxacin and levofloxacin, while hepatotoxicity is not mentioned as an adverse reaction in the product information for paracetamol (except in overdose).9-13 It is possible that in some of these cases, one or more of the other suspected drugs may be a more likely cause of the adverse reaction but in most cases, it is difficult to assign causality with any degree of certainty. Time to onset was reported in 59 of the 67 ICSRs. It ranged from 11 days before administration to three years, but apart from these two outliers and one other case in which onset was before administration, the range was from the same day that administration began to about four months with a median of six days. The report in which onset was three years after administration began (Case 1) and the two reports which described onset before administration (Cases 27 and 64) can be eliminated as indicating ceftriaxone as a possible cause but of the remaining 56 reports which reported onset dates, the onset in 52 cases ranged from the same day to 17 days, in an unusual example of consistency in spontaneous reports, which is suggestive of ceftriaxone as a cause. The time to onset is shorter than that reported with penicillin-induced hepatotoxicity but consistent with that reported with other reports with ceftriaxone.3- 7,14,15 The outcome was stated in 59 reports. The patients were reported as recovered or recovering in 52 cases and not recovered in the remaining seven reports. Three of the 52 cases documenting recovery had an implausible time to onset as discussed above, so of the remaining 49 cases where the outcome was reported as recovered or recovering, the drug was withdrawn in 47 cases, which included eight cases in which the drug was stopped before onset. In the two remaining cases, the drug was continued in one and the action taken with the drug was unknown in the other. It should be noted that in reports of other antibioticinduced hepatotoxicity involving both flucloxacillin and amoxicillin/clavulanic acid, it is common that the hepatic reaction develops after the drug has been stopped.14,15 In the cases where the patients had not recovered, the drug was withdrawn in six cases, including three in which the drug was withdrawn before onset and the action taken with the drug was unknown in the remaining case. This high degree of recovery after withdrawal is strong evidence for a causal role of ceftriaxone. While for those reports with other suspected drugs, those other drugs were also often withdrawn, also, for the 27 cases in which there were no other suspected drugs, the outcome was stated in 22 of the reports. The patients recovered after drug withdrawal in 19 cases and had not recovered in the remaining three cases. The drug was withdrawn in two of those cases and the action taken with the drug was unknown in the other case. This information confirms the evidence for a causal role for ceftriaxone. Hepatotoxicity is uncommon but well known to occur with antibacterials, particularly penicillins.16 The same publication notes that clinical hepatotoxicity seems extremely rare with cephalosporins although a transient elevation of transaminases is quite common varying from 0.7% of patients on cefixime to 11% of patients taking cefaclor. As stated above, the product information for ceftriaxone notes that hepatic enzymes increased is reported as one of the most frequently reported adverse reactions.1 There are, however, a number of reports in the literature of hepatitis in association with ceftriaxone. Although only one of the patients was elderly, time to onset ranged from three days to three weeks after commencing ceftriaxone with most cases describing onset within a few days,3-7 consistent with the cases described in this assessment. In addition, when other hepatic terms from the High-Level Terms (HLTs) of “Cholestasis and jaundice”, “Hepatic failure and associated disorders” and “Hepatocellular damage and hepatitis NEC” are included, there are 218 additional reports of hepatotoxicity in association with ceftriaxone in patients aged 75 years or greater. Commonly reported terms include an additional 70 reports of cholestasis, 33 separate reports of hepatocellular injury, 26 separate reports of jaundice, 21 separate reports of hepatitis cholestatic and 20 separate reports of the HLT, “Hepatic failure and associated disorders”. As noted in the Introduction, hepatitis can be designated as hepatocellular or cholestatic. Of those reports where this designation could be made on the basis of enzyme values, there were about 15 reports of hepatocellular hepatitis and about the same number of reports of cholestatic hepatitis with a handful of reports of mixed hepatitis. On the basis of other liver reactions reported, however, such as cholestasis and jaundice, cholestatic hepatitis may be more common in association with ceftriaxone. It is interesting to speculate on the possibility of a mechanism to explain why patients 75 years and older may be susceptible to this association. Renal clearance of ceftriaxone is 5 - 12 ml/min with 50 - 60% of ceftriaxone excreted unchanged in the urine, primarily by glomerular filtration, while 40 - 50% is excreted unchanged in the bile. The elimination half-life of total ceftriaxone in adults is about 8 hours. The product information notes that in patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone provided hepatic function is not impaired. Only in cases of preterminal renal failure (creatinine clearance < 10 ml/min) should the ceftriaxone dosage not exceed 2 g daily. However, the product information also states that in older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.1 Adverse drug reactions are well known as a major problem in the elderly population and reduced renal function is an important reason.17 It is possible that the prolonged clearance in elderly patients may result in such patients being exposed to ceftriaxone for a longer period of time and a resulting increased risk of hepatotoxicity. It is noteworthy that increasing age is a risk factor for the development of hepatotoxicity in association with two penicillin antibiotics.18,19 It is significant that the association is not disproportionate in the database as a whole, but in the 75 years and older age group, the IC value is 0.86 with an IC025 value of 0.25. In VigiBase as a whole, there are 16,438,393 reports as at 11 February 2018. Of those, 1,543,092 involve patients aged 75 years and older (9.39%). For ceftriaxone, of the 96,426 reports submitted, 12,285 involve patients aged 75 years and older (12.74%). For hepatitis, there are 45,806 reports with 4,835 involving patients aged 75 years and older (10.55%). For the association of ceftriaxone and hepatitis, there are 240 reports with 70 reports (three additional reports since the date of this assessment) involving patients aged 75 years and older (28.93%). This crude statistical assessment indicates that hepatitis in association with ceftriaxone occurs two to three times more commonly than would be otherwise expected. In conclusion, there is a signal for the association of ceftriaxone with hepatitis in patients aged 75 years and older. There are a relatively large number of reports of hepatitis, a consistent time to onset and a consistent response to drug withdrawal. Raised liver enzymes is mentioned in the product information and there are five reports of hepatitis in association with ceftriaxone." ;
                           rdfs:label "Discussion and Conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Dosage_for_ceftriaxone
:Dosage_for_ceftriaxone rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "was most commonly one or two grams daily" ;
                        rdfs:label "Dosage for ceftriaxone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Dr_Ian_Boyd
:Dr_Ian_Boyd rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Ian" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Boyd" ;
             rdfs:label "Dr Ian Boyd" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Dronedarone
:Dronedarone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01BD07" ;
             rdfs:label "Dronedarone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Econazole
:Econazole rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D01AC03" ,
                                                                        "G01AF05" ,
                                                                        "G01AF20" ;
           rdfs:label "Econazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Enalapril
:Enalapril rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09AA02" ,
                                                                        "C09BA02" ,
                                                                        "C09BB02" ,
                                                                        "C09BB06" ;
           rdfs:label "Enalapril" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Enoxaparin
:Enoxaparin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AB05" ;
            rdfs:label "Enoxaparin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Eosinophilia
:Eosinophilia rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "D721" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10014950 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Eosinophilia" ;
              rdfs:label "Eosinophilia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Erythromycin
:Erythromycin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D10AF02" ,
                                                                           "D10AF52" ,
                                                                           "J01FA01" ,
                                                                           "S01AA17" ;
              rdfs:label "Erythromycin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Esomeprazole
:Esomeprazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC05" ,
                                                                           "A02BD06" ,
                                                                           "M01AE52" ;
              rdfs:label "Esomeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ethambutol
:Ethambutol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J04AK02" ,
                                                                         "J04AM03" ,
                                                                         "J04AM06" ;
            rdfs:label "Ethambutol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ezetimibe
:Ezetimibe rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AX09" ,
                                                                        "C10BA02" ,
                                                                        "C10BA05" ,
                                                                        "C10BA06" ;
           rdfs:label "Ezetimibe" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Flucloxacillin
:Flucloxacillin rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01CF05" ,
                                                                             "J01CR50" ;
                rdfs:label "Flucloxacillin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Fluindione
:Fluindione rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AA12" ;
            rdfs:label "Fluindione" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Fluticasone
:Fluticasone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D07AC17" ,
                                                                          "R01AD08" ,
                                                                          "R01AD58" ,
                                                                          "R03AK06" ,
                                                                          "R03AK11" ,
                                                                          "R03BA05" ;
             rdfs:label "Fluticasone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#FolicAcid
:FolicAcid rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B03AE01" ,
                                                                        "B03AE02" ,
                                                                        "B03BB01" ,
                                                                        "B03BB51" ;
           rdfs:label "Folic Acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Formoterol
:Formoterol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03AC13" ,
                                                                         "R03AK07" ,
                                                                         "R03AK08" ,
                                                                         "R03AK09" ,
                                                                         "R03AK11" ,
                                                                         "R03AL05" ;
            rdfs:label "Formoterol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Frequently_reported_ADR_for_ceftriaxone
:Frequently_reported_ADR_for_ceftriaxone rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Eosinophilia ,
                                                                                                                  :Hepatic_enzymes_increased ,
                                                                                                                  :Leucopenia ,
                                                                                                                  :Rash ,
                                                                                                                  :Thrombocytopenia ,
                                                                                                                  :diarrhoea ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                                         mp:references :Ref.1 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased.1" ;
                                         rdfs:label "Frequently reported ADR for ceftriaxone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Furosemide
:Furosemide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA01" ,
                                                                         "C03CB01" ,
                                                                         "C03EB01" ,
                                                                         "G01AE10" ;
            rdfs:label "Furosemide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Gemfibrozil
:Gemfibrozil rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AB04" ;
             rdfs:label "Gemfibrozil" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Gentamicin
:Gentamicin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D06AX07" ,
                                                                         "J01GB03" ,
                                                                         "S01AA11" ,
                                                                         "S02AA14" ,
                                                                         "S03AA06" ;
            rdfs:label "Gentamicin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Gliclazide
:Gliclazide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BB09" ;
            rdfs:label "Gliclazide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Halothane
:Halothane rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N01AB01" ;
           rdfs:label "Halothane" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Heparin
:Heparin rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AB01" ,
                                                                      "B01AB51" ,
                                                                      "C05BA03" ,
                                                                      "C05BA53" ,
                                                                      "S01XA14" ;
         rdfs:label "Heparin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#HepaticEnzymesIncreased
:HepaticEnzymesIncreased rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10056910 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "GGT increased" ;
                         rdfs:label "GGT increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Hepatic_enzymes_increased
:Hepatic_enzymes_increased rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019662 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hepatic enzymes increased" ;
                           rdfs:label "Hepatic enzymes increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Hepatic_failure_and_associated_disorders
:Hepatic_failure_and_associated_disorders rdf:type owl:NamedIndividual ,
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019664 ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hepatic failure and associated disorders" ;
                                          rdfs:label "Hepatic failure and associated disorders" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Hepatic_function_abnormal
:Hepatic_function_abnormal rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019670 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hepatic function abnormal" ;
                           rdfs:label "Hepatic function abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Hepatitis
:Hepatitis rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K759" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019717 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hepatitis" ;
           rdfs:label "Hepatitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#HepatocellularLiverInjury
:HepatocellularLiverInjury rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K76.9" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019837 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hepatocellular injury" ;
                           rdfs:label "Hepatocellular liver injury" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Hepatotoxicity_and_penicillins-cephalosporins
:Hepatotoxicity_and_penicillins-cephalosporins rdf:type owl:NamedIndividual ,
                                                        <http://purl.obolibrary.org/obo/OAE_0001182> ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :hepatotoxicity ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> :Cephalosporins ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Penicillin ;
                                               mp:references :Ref.16 ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Hepatotoxicity is uncommon but well known to occur with antibacterials, particularly penicillins.16 The same publication notes that clinical hepatotoxicity seems extremely rare with cephalosporins although a transient elevation of transaminases is quite common varying from 0.7% of patients on cefixime to 11% of patients taking cefaclor." ;
                                               rdfs:label "Hepatotoxicity and penicillins-cephalosporins" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Hydrocortisone
:Hydrocortisone rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "H02AB09" ;
                rdfs:label "Hydrocortisone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Hydroxyzine
:Hydroxyzine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BB01" ,
                                                                          "N05BB51" ;
             rdfs:label "Hydroxyzine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#IC025_value_for_Ceftriaxone_and_Hepatitis_above_75_years
:IC025_value_for_Ceftriaxone_and_Hepatitis_above_75_years rdf:type owl:NamedIndividual ,
                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_information_component> :IC_value_for_Ceftriaxone_and_Hepatitis_above_75_years ;
                                                          mp:references :Ceftriaxone ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "07/10/2017"^^xsd:date ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 75 ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.25 ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 67 ;
                                                          rdfs:label "IC025 value for Ceftriaxone and Hepatitis above 75 years" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#IC_value_for_Ceftriaxone_and_Hepatitis_above_75_years
:IC_value_for_Ceftriaxone_and_Hepatitis_above_75_years rdf:type owl:NamedIndividual ,
                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "7/10/2017"^^xsd:date ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 75 ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.86 ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 67 ;
                                                       rdfs:label "IC value for Ceftriaxone and Hepatitis above 75 years" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Indapamide
:Indapamide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03BA11" ,
                                                                         "C09BX01" ,
                                                                         "G01AE10" ;
            rdfs:label "Indapamide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Infections
:Infections rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "A49.9" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10021789 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Infection" ;
            rdfs:label "Infections" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Intramuscular_administration
:Intramuscular_administration rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Intake_Form> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> "injected (intramuscular)" ;
                              rdfs:label "Intramuscular administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Intravenous_administration
:Intravenous_administration rdf:type owl:NamedIndividual ,
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Intake_Form> ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> "injected (intraveneous)" ;
                            rdfs:label "Intravenous administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ipratropium
:Ipratropium rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03BB01" ;
             rdfs:label "Ipratropium" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Irbesartan
:Irbesartan rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09CA04" ;
            rdfs:label "Irbesartan" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Iron
:Iron rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A11AA01" ,
                                                                   "B03AA01" ,
                                                                   "B03AA02" ,
                                                                   "B03AA03" ,
                                                                   "B03AA06" ,
                                                                   "B03AA10" ,
                                                                   "B03AD02" ,
                                                                   "B03AE01" ,
                                                                   "B03AE02" ,
                                                                   "B03AE03" ,
                                                                   "B03AE04" ;
      rdfs:label "Iron" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Isoniazid
:Isoniazid rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J04AC01" ,
                                                                        "J04AC51" ,
                                                                        "J04AM01" ,
                                                                        "J04AM02" ,
                                                                        "J04AM03" ,
                                                                        "J04AM04" ,
                                                                        "J04AM05" ,
                                                                        "J04AM06" ;
           rdfs:label "Isoniazid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Jaundice
:Jaundice rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R17" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10023126 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Jaundice" ;
          rdfs:label "Jaundice" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Labetalol
:Labetalol rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AG01" ,
                                                                        "C07BG01" ,
                                                                        "C07CG01" ;
           rdfs:label "Labetalol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Lactulose
:Lactulose rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A06AD11" ;
           rdfs:label "Lactulose" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Lamotrigine
:Lamotrigine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AX09" ;
             rdfs:label "Lamotrigine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Lercanidipine
:Lercanidipine rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09BB02" ;
               rdfs:label "Lercanidipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Leucopenia
:Leucopenia rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "D70" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10024384 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Leukopenia" ;
            rdfs:label "Leucopenia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Leuprorelin
:Leuprorelin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L02AE02" ;
             rdfs:label "Leuprorelin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Levofloxacin
:Levofloxacin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BD10" ,
                                                                           "J01MA12" ,
                                                                           "J01RA05" ,
                                                                           "S01AE05" ;
              rdfs:label "Levofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Levothyroxine
:Levothyroxine rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "H03AA01" ;
               rdfs:label "Levothyroxine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Literature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                          mp:references :Ref.1 ,
                                        :Ref.4 ,
                                        :Ref.5 ,
                                        :Ref.6 ,
                                        :Ref.7 ,
                                        :Ref.8 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The product literature does not refer to hepatitis. Currently, the only hepatic reaction mentioned in the adverse drug reaction section of the product labels is hepatic enzymes increased which is reported as one of the most frequently reported adverse reactions.1 There are a number of reports in the literature of hepatitis in association with ceftriaxone. Nadelman and co-workers reported the development of granulocytopenia, fever, hepatitis, and Clostridium difficile-associated diarrhea after three weeks treatment with intravenous ceftriaxone.4 Longo et al described an 80-year-old male who developed hepatitis shortly after starting oral ceftriaxone. Although transaminases returned to baseline after ceftriaxone withdrawal, there was development of haemolytic anaemia and erythoblastocytopenia.5 Bell and co-workers described an adolescent who experienced acute haemolytic anaemia and severe hepatitis after four days of ceftriaxone therapy. All hepatic enzymes increased dramatically to levels over 20,000 IU/L and the outcome was fatal.6 Peker et al described a 12-year-old who developed hepatitis after three days of ceftriaxone for tonsillitis. After ceftriaxone withdrawal and the use of steroids, the patient recovered after about ten weeks.7 Kaur and Singh reported the development of cholestatic hepatitis in a 24-year-old female patient a few days after the use of intravenous ceftriaxone. The patient recovered after three weeks.8" ;
                          rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#LiverInjury
:LiverInjury rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "S361" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10067125 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Liver injury" ;
             rdfs:label "Liver injury" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Longo_et_al__report
:Longo_et_al__report rdf:type owl:NamedIndividual ,
                              <http://purl.obolibrary.org/obo/OAE_0001197> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                              :erythroblastocytopenia ,
                                                                                              :haemolytic_anaemia ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                     mp:references :Ref.5 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Longo et al described an 80-year-old male who developed hepatitis shortly after starting oral ceftriaxone. Although transaminases returned to baseline after ceftriaxone withdrawal, there was development of haemolytic anaemia and erythoblastocytopenia.5" ;
                     rdfs:label "Longo et al  report" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Lorazepam
:Lorazepam rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA06" ,
                                                                        "N05BA56" ;
           rdfs:label "Lorazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Lormetazepam
:Lormetazepam rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05CD06" ;
              rdfs:label "Lormetazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Macrogol
:Macrogol rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A06AD15" ;
          rdfs:label "Macrogol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Manidipine
:Manidipine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08CA11" ,
                                                                         "C09BB12" ;
            rdfs:label "Manidipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Mechanism_of_ceftriaxone
:Mechanism_of_ceftriaxone rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Ceftriaxone is a cephalosporin antibiotic which inhibits bacterial cell wall synthesis following attachment to PBPs. This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death. It is used in the treatment of a large variety of infections ." ;
                          rdfs:label "Mechanism of ceftriaxone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#MetabolismDisorder
:MetabolismDisorder rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E88.9" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10000546 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Metabolism disorders NEC" ;
                    rdfs:label "Metabolism disorder" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Methotrexate
:Methotrexate rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01BA01" ,
                                                                           "L04AX03" ;
              rdfs:label "Methotrexate" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Methylprednisolone
:Methylprednisolone rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D07AA01" ,
                                                                                 "D07AC14" ,
                                                                                 "D07CA02" ,
                                                                                 "D10AA02" ,
                                                                                 "H02AB04" ,
                                                                                 "H02BX01" ,
                                                                                 "S01CA08" ;
                    rdfs:label "Methylprednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Metoclopramide
:Metoclopramide rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A03FA01" ;
                rdfs:label "Metoclopramide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Metopimazine
:Metopimazine rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A04AD05" ;
              rdfs:label "Metopimazine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Metoprolol
:Metoprolol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AB02" ,
                                                                         "C07AB52" ,
                                                                         "C07BB02" ,
                                                                         "C07BB52" ,
                                                                         "C07CB02" ,
                                                                         "C07FB02" ;
            rdfs:label "Metoprolol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Metoprolol_Felodipine
:Metoprolol_Felodipine rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07FB02" ;
                       rdfs:label "Metoprolol / Felodipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Metronidazole
:Metronidazole rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A01AB17" ,
                                                                            "A02BD01" ,
                                                                            "A02BD02" ,
                                                                            "A02BD03" ,
                                                                            "A02BD08" ,
                                                                            "A02BD11" ,
                                                                            "D06BX01" ,
                                                                            "G01AF01" ,
                                                                            "G01AF20" ,
                                                                            "J01RA03" ,
                                                                            "J01RA04" ,
                                                                            "J01RA10" ,
                                                                            "J01XD01" ,
                                                                            "P01AB01" ,
                                                                            "P01AB51" ;
               rdfs:label "Metronidazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Mianserin
:Mianserin rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AX03" ;
           rdfs:label "Mianserin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Milnacipran
:Milnacipran rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AX17" ;
             rdfs:label "Milnacipran" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Moxifloxacin
:Moxifloxacin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01MA14" ,
                                                                           "S01AE07" ;
              rdfs:label "Moxifloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#NSAIDS
:NSAIDS rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M01A" ;
        rdfs:label "NSAIDS" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Nadelman_report
:Nadelman_report rdf:type owl:NamedIndividual ,
                          <http://purl.obolibrary.org/obo/OAE_0001197> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Clostridium_difficile-associated_diarrhea ,
                                                                                          :Hepatitis ,
                                                                                          :fever ,
                                                                                          :granulocytopenia ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                 mp:references :Ref.4 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Nadelman and co-workers reported the development of granulocytopenia, fever, hepatitis, and Clostridium difficile-associated diarrhea after three weeks treatment with intravenous ceftriaxone.4" ;
                 rdfs:label "Nadelman report" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Nausea
:Nausea rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R11" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028813 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Nausea" ;
        rdfs:label "Nausea" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Nefopam
:Nefopam rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02BG06" ;
         rdfs:label "Nefopam" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Netilmicin
:Netilmicin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01GB07" ,
                                                                         "S01AA23" ;
            rdfs:label "Netilmicin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Neutropenia
:Neutropenia rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "D70.9" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10029354 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Neutropenia" ;
             rdfs:label "Neutropenia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Nicardipine
:Nicardipine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08CA04" ;
             rdfs:label "Nicardipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Nicergoline
:Nicergoline rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C04AE02" ;
             rdfs:label "Nicergoline" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Nifedipine
:Nifedipine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07FB03" ;
            rdfs:label "Nifedipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Nifuroxazide
:Nifuroxazide rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A07AX03" ;
              rdfs:label "Nifuroxazide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Nitrendipine
:Nitrendipine rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08" ;
              rdfs:label "Nitrendipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Norfloxacin
:Norfloxacin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "S01AE02" ;
             rdfs:label "Norfloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ofloxacin
:Ofloxacin rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01MA01" ,
                                                                        "J01RA09" ,
                                                                        "S01AE01" ,
                                                                        "S02AA16" ;
           rdfs:label "Ofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Older_age
:Older_age rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10014348 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Elderly" ;
           rdfs:label "Older age" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Omeprazole
:Omeprazole rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC01" ,
                                                                         "A02BC05" ,
                                                                         "A02BD01" ,
                                                                         "A02BD05" ,
                                                                         "A02BD06" ,
                                                                         "M01AE52" ;
            rdfs:label "Omeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#OralContraceptives
:OralContraceptives rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G03A" ;
                    rdfs:label "Oral contraceptives" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Oral_administration
:Oral_administration rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Intake_Form> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> "oral" ;
                     rdfs:label "Oral administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#OverallReportsInVigibase
:OverallReportsInVigibase rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_unconfirmed_adverse_effect> :Hepatitis ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 67 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 21 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 45 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 94 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_median_age> 84 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 75 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                          rdfs:label "Overall reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Oxazepam
:Oxazepam rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA04" ;
          rdfs:label "Oxazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Pantoprazole
:Pantoprazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC02" ;
              rdfs:label "Pantoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Parenterally_administration
:Parenterally_administration rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Intake_Form> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> "injected" ;
                             rdfs:label "Parenterally administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Paroxetine
:Paroxetine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AB05" ;
            rdfs:label "Paroxetin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Pathophysiology_of_hepatitis
:Pathophysiology_of_hepatitis rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                                       :HepatocellularLiverInjury ,
                                                                                                       :LiverInjury ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> :AnabolicSteroids ,
                                                                                              :NSAIDS ,
                                                                                              :OralContraceptives ,
                                                                                              :Statins ,
                                                                                              :Sulfadrugs ,
                                                                                              :Tetracyclines ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Acetaminophen ,
                                                                                             :Amiodarone ,
                                                                                             :Antiseizure_medication ,
                                                                                             :Chlorpromazine ,
                                                                                             :Erythromycin ,
                                                                                             :Halothane ,
                                                                                             :Isoniazid ,
                                                                                             :Methotrexate ,
                                                                                             :methyldopa ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> ;
                              mp:references :Ref.2 ,
                                            :Ref.3 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "\"Hepatitis refers to an inflammatory condition of the liver. It’s commonly caused by a viral infection, but there are other possible causes of hepatitis including as a secondary result of medications, drugs, toxins, and alcohol. A large number of drugs have been implicated as a cause of hepatitis. These include paracetamol, non-steroidal antiinflammatory drugs (NSAIDs), amiodarone, anabolic steroids, oral contraceptives, chlorpromazine, erythromycin, halothane, methyldopa, isoniazid, methotrexate, statins, sulfa drugs, tetracyclines, amoxicillin-clavulanate and some anti-seizure medicines.2 Hepatitis is a preferred term in both WHO-ART and MedDRA, although in MedDRA there are many other related terms. As VigiLyze no longer supports WHO-ART, only MedDRA terms will be discussed in this assessment. The Council for International Organizations for Medical Sciences (CIOMS) recommends that in the absence of a histologically established diagnosis, the term liver injury is to be preferred to hepatocellular damage; the latter should be used only when there is pertinent histological evidence.3 Specific terms such hepatitis should be used only when the condition has been confirmed by histological or other means. It is, however, common practice for clinicians to use the term hepatitis. Liver injury (or hepatitis) can be further characterised as hepatocellular or cholestatic if the pertinent values of specific liver enzymes are available. Hepatocellular is defined when the ratio of the serum activity of alanine aminotransferase (ALT) expressed as a multiple of the upper limit of normal (ULN) divided by the serum activity of alkaline phosphatase (AP) expressed as a multiple of the ULN is greater than or equal to five. Cholestatic is defined when that ratio is less than two. The term mixed is used for values between two and five.3\"" ;
                              rdfs:label "Pathophysiology of hepatitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient10
:Patient10 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 82 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient11
:Patient11 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 76 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient12
:Patient12 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 77 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient13
:Patient13 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 75 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient14
:Patient14 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 94 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient15
:Patient15 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 84 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 15" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient16
:Patient16 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 75 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 16" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient17
:Patient17 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 88 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient18
:Patient18 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 90 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient19
:Patient19 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 77 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 84 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient20
:Patient20 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 86 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient21
:Patient21 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 87 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 21" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient22
:Patient22 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 82 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 22" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient23
:Patient23 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 86 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 23" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient24
:Patient24 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 86 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 24" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient25
:Patient25 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 25" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient26
:Patient26 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 80 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 26" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient27
:Patient27 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 76 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 27" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient28
:Patient28 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 90 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 28" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient29
:Patient29 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 87 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 29" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 76 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient30
:Patient30 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 79 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 30" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient31
:Patient31 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 83 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 31" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient32
:Patient32 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 88 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 32" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient33
:Patient33 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 80 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 33" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient34
:Patient34 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 76 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 34" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient35
:Patient35 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 86 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 35" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient36
:Patient36 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 76 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 36" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient37
:Patient37 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 84 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 37" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient38
:Patient38 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 83 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 38" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient39
:Patient39 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 82 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 39" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 76 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient40
:Patient40 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 80 ;
           rdfs:label "Patient 40" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient41
:Patient41 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 85 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 41" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient42
:Patient42 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 92 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 42" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient43
:Patient43 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 43" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient44
:Patient44 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 44" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient45
:Patient45 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 83 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 45" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient46
:Patient46 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 84 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 46" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient47
:Patient47 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 89 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 47" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient48
:Patient48 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 80 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 48" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient49
:Patient49 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 84 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 49" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 92 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient50
:Patient50 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 86 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 50" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient51
:Patient51 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 85 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 51" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient52
:Patient52 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 91 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 52" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient53
:Patient53 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 87 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 53" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient54
:Patient54 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 81 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 54" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient55
:Patient55 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 87 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 55" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient56
:Patient56 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 81 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 56" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient57
:Patient57 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 90 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 57" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient58
:Patient58 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 86 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 58" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient59
:Patient59 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 87 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 59" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 82 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient60
:Patient60 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 85 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 60" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient61
:Patient61 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 84 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 61" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient62
:Patient62 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 91 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 62" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient63
:Patient63 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 82 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 63" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient64
:Patient64 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 64" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient65
:Patient65 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 83 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 65" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient66
:Patient66 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 83 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 66" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient67
:Patient67 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 82 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 67" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient7
:Patient7 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 88 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient8
:Patient8 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 89 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Patient9
:Patient9 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 90 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Peker_report
:Peker_report rdf:type owl:NamedIndividual ,
                       <http://purl.obolibrary.org/obo/OAE_0001197> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
              mp:references :Ref.7 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Peker et al described a 12-year-old who developed hepatitis after three days of ceftriaxone for tonsillitis. After ceftriaxone withdrawal and the use of steroids, the patient recovered after about ten weeks ." ;
              rdfs:label "Peker report" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Penicillin
:Penicillin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01C" ;
            rdfs:label "Penicillin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Perindopril
:Perindopril rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09AA04" ;
             rdfs:label "Perindopril" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Pipobroman
:Pipobroman rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01AX02" ;
            rdfs:label "Pipobroman" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Piribedil
:Piribedil rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N04BC08" ;
           rdfs:label "Piribedil" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Piroxicam
:Piroxicam rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M01AC01" ,
                                                                        "M02AA07" ,
                                                                        "S01BC06" ;
           rdfs:label "Piroxicam" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Plantago_Ovata
:Plantago_Ovata rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A06AC01" ;
                rdfs:label "Plantago Ovata" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Polygeline
:Polygeline rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B05AA07" ;
            rdfs:label "Polygeline" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Potassium
:Potassium rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B05XA17" ,
                                                                        "C03AB01" ,
                                                                        "C03AB02" ,
                                                                        "C03AB03" ,
                                                                        "C03AB04" ,
                                                                        "C03AB05" ,
                                                                        "C03AB06" ,
                                                                        "C03AB07" ,
                                                                        "C03AB08" ,
                                                                        "C03AB09" ,
                                                                        "C03BB02" ,
                                                                        "C03BB03" ,
                                                                        "C03BB04" ,
                                                                        "C03BB05" ,
                                                                        "C03BB07" ,
                                                                        "C03CB01" ,
                                                                        "C03CB02" ;
           rdfs:label "Potassium" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Pravastatin
:Pravastatin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA03" ,
                                                                          "C10BA03" ,
                                                                          "C10BX02" ;
             rdfs:label "Pravastatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Prednisolone
:Prednisolone rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A01AC54" ,
                                                                           "A07EA01" ,
                                                                           "C05AA04" ,
                                                                           "D07AA03" ,
                                                                           "D07BA01" ,
                                                                           "D07CA03" ,
                                                                           "D07XA02" ,
                                                                           "H02AB06" ,
                                                                           "R01AD02" ,
                                                                           "R01AD52" ,
                                                                           "S01BA04" ,
                                                                           "S01BB02" ,
                                                                           "S01CA02" ,
                                                                           "S01CB02" ,
                                                                           "S02BA03" ,
                                                                           "S02CA01" ,
                                                                           "S03BA02" ,
                                                                           "S03CA02" ,
                                                                           "V03AB05" ;
              rdfs:label "Prednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Pregabalin
:Pregabalin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AX24" ;
            rdfs:label "Pregabalin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Pristinamycin
:Pristinamycin rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01FG01" ;
               rdfs:label "Pristinamycin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Propofol
:Propofol rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N01AX10" ;
          rdfs:label "Propofol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Propranolol
:Propranolol rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AA05" ;
             rdfs:label "Propranolol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Pyrazinamide
:Pyrazinamide rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J04AK01" ,
                                                                           "J04AM05" ,
                                                                           "J04AM06" ;
              rdfs:label "Pyrazinamide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ramipril
:Ramipril rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09AA05" ,
                                                                       "C09BA05" ,
                                                                       "C09BB05" ,
                                                                       "C09BB07" ,
                                                                       "C10BX04" ,
                                                                       "C10BX06" ;
          rdfs:label "Ramipril" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Rash
:Rash rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R21" ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037844 ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Rash" ;
      rdfs:label "Rash" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Reduced_renal_function
:Reduced_renal_function rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Potential_Confounder> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10021523 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Impaired renal function" ;
                        rdfs:label "Reduced renal function" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium. Summary  of Product Characteristics for ceftriaxone  (Rocephin). Available from:  http://www.medicines.org.uk/emc/  product/7933/smpc. Accessed: 17 January  2018.  " ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium. Summary  of Product Characteristics for Augmentin 625  mg Tablets (amoxicillin/clavulanic acid).  Available from:  https://www.medicines.org.uk/emc/product/2  81/ smpc. Accessed: 8 February 2018.  " ;
        rdfs:label "Ref.10" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium. Summary  of Product Characteristics for Ciproxin Tablets  500 mg (ciprofloxacin). Available  from:https://www.medicines.org.uk/emc/prod  uct/6153/smpc. Accessed: 8 February 2018.  " ;
        rdfs:label "Ref.11" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.12
:Ref.12 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium. Summary  of Product Characteristics for Ofloxacin 400 mg  Tablets (ofloxacin). Available from:  https://www.  medicines.org.uk/emc/product/8480/smpc.  Accessed: 8 February 2018.  " ;
        rdfs:label "Ref.12" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.13
:Ref.13 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium. Summary  of Product Characteristics for Levofloxacin 500  mg Film-coated tablets (levofloxacin).  Available from:  https://www.medicines.org.uk/emc/product/6  1291/ smpc. Accessed: 8 February 2018." ;
        rdfs:label "Ref.13" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.14
:Ref.14 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Devereaux BM, Crawford DH, Purcell P, Powell  LH, Roeser HP. Flucloxacillin associated  cholestatic hepatitis. An Australian and  Swedish epidemic? Eur J Clin Pharmacol  1995;49:81-85.  " ;
        rdfs:label "Ref.14" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.15
:Ref.15 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Fontana RJ, Shakil O, Greenson JK, Boyd I,  Lee WM. Acute liver failure due to amoxicillin  and amoxicillin/clavulanate. Dig Dis Sci  2005;50:1785- 90.  " ;
        rdfs:label "Ref.15" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.16
:Ref.16 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "George DK, Crawford DHG. Antibacterialinduced hepatotoxicity: incidence, prevention  and management. Drug Safe 1996;15:79-85.  " ;
        rdfs:label "Ref.16" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.17
:Ref.17 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Nair NP, Chalmers L, Bereznicki BJ, Curtain C,  Peterson GM, Connolly M, Bereznicki LR.  Adverse drug reaction-related hospitalizations  in elderly Australians: a prospective crosssectional study in two Tasmanian hospitals.  Drug Saf 2017;40:597-606.  " ;
        rdfs:label "Ref.17" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.18
:Ref.18 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Fairley CK, McNeil JJ, Desmond P, Smallwood
R, Young H, Forbes A, Purcell P, Boyd I. Risk
factors for development of flucloxacillin
associated jaundice. BMJ 1993;306:233-5.""" ;
        rdfs:label "Ref.18" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.19
:Ref.19 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Thomson JA, Fairley CK, Ugoni AM, Forbes AB,  Purcell PM, Desmond PV, McNeil JJ. Risk  factors for the development of amoxicillinclavulanic acid associated jaundice. Med J  Aust 1995;162:638-40.  " ;
        rdfs:label "Ref.19" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "US National Library of Medicine. Medline Plus.  Drug-induced liver injury. Available from:  https:// medlineplus.  gov/ency/article/000226.htm. Accessed: 17  January 2018.  " ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The Council for International Organizations of  Medical Sciences (CIOMS). Reporting Adverse  Drug Reactions: Definitions of Terms and  Criteria for their Use. CIOMS, Geneva, 1999.  Available from: https://cioms.ch/wpcontent/uploads/2017/01/  reporting_adverse_drug.pdf. Accessed: 16  February 2018.  " ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Nadelman RB, Arlin Z, Wormser GP. Lifethreatening complications of empiric  ceftriaxone therapy for 'seronegative Lyme  disease'. South Med J 1991; 84: 1263-1265. " ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Longo F, Hastier P, Buckley MJ, Chichmanian  RM, Delmont JP. Acute hepatitis, autoimmune  hemolytic anemia, and erythroblastocytopenia  induced by ceftriaxone. Am J Gastroenterol  1998; 93: 836-837.  6. Bell MJ, Stockwell DC, Luban NL, Shirey RS,  Shaak L, Ness PM, Wong EC. Ceftriaxoneinduced hemolytic anemia and hepatitis in an  adolescent with hemoglobin SC disease.  Pediatr Crit Care Med 2005; " ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Bell MJ, Stockwell DC, Luban NL, Shirey RS,
Shaak L, Ness PM, Wong EC. Ceftriaxoneinduced hemolytic anemia and hepatitis in an
adolescent with hemoglobin SC disease.
Pediatr Crit Care Med 2005; 6: 363-366.""" ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Peker E, Cagan E, Dogan M. Ceftriaxoneinduced toxic hepatitis. World J Gastroenterol  2009;15: 2669-2671.  " ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kaur I,Singh J.  Cholestatichepatitiswithintravenous  ceftriaxone. Indian J Pharmacol 2011;43:474-  75.  " ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium. Summary  of Product Characteristics for Flagyl 400 mg  Tablets (metronidazole). Available from:  https://  www.medicines.org.uk/emc/product/6380/sm  pc. Accessed: 8 February 2018.  " ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#RenalFailure
:RenalFailure rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N19" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10038435 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Renal failure" ;
              rdfs:label "Renal failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetaminophen ,
                                                                                    :Chlortalidone ,
                                                                                    :Ipratropium ,
                                                                                    :Methylprednisolone ,
                                                                                    :Salbutamol ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Clarithromycin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report10
:Report10 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report11
:Report11 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetaminophen ,
                                                                                     :Alprazolam ,
                                                                                     :Hydroxyzine ,
                                                                                     :Indapamide ,
                                                                                     :Irbesartan ,
                                                                                     :Metoclopramide ,
                                                                                     :Metoprolol_Felodipine ,
                                                                                     :Paroxetine ,
                                                                                     :Tramadol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Metronidazole ,
                                                                                           :Pristinamycin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report12
:Report12 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Gemfibrozil ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient12 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Acetaminophen ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report13
:Report13 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :Nausea ,
                                                                                   :Rash ,
                                                                                   :Vomitting ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient13 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report14
:Report14 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                     :Alprazolam ,
                                                                                     :Econazole ,
                                                                                     :Gliclazide ,
                                                                                     :Hydroxyzine ,
                                                                                     :Irbesartan ,
                                                                                     :Rotigotine ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Benserazide_/_Levodopa> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient14 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Clozapine ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report15
:Report15 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                     :Atorvastatin ,
                                                                                     :Fluindione ,
                                                                                     :Ofloxacin ,
                                                                                     :Oxazepam ,
                                                                                     :Paroxetine ,
                                                                                     :Piribedil ,
                                                                                     :Prednisolone ,
                                                                                     :Verapamil ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient15 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 15" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report16
:Report16 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Clobazam ,
                                                                                     :Dalteparin ,
                                                                                     :Valaciclovir ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#sulfamethoxazole/trimethoprim> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient16 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ciprofloxacin ,
                                                                                           :Dalteparin ,
                                                                                           :Methotrexate ,
                                                                                           :Prednisolone ,
                                                                                           :Rituximab ,
                                                                                           :Spiramycin ,
                                                                                           :Vincristine ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 16" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report17
:Report17 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Fluindione ,
                                                                                     :FolicAcid ,
                                                                                     :Furosemide ,
                                                                                     :Iron ,
                                                                                     :Potassium ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient17 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report18
:Report18 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Allopurinol ,
                                                                                     :Bisoprolol ,
                                                                                     :Colecalciferol ,
                                                                                     :Econazole ,
                                                                                     :Fluindione ,
                                                                                     :Plantago_Ovata ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient18 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report19
:Report19 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :Jaundice ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient19 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Fluindione ,
                                                                                           :Methylprednisolone ,
                                                                                           :Nicardipine ,
                                                                                           :Ramipril ,
                                                                                           :Vildagliptin ,
                                                                                           <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Enoxaparin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report20
:Report20 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Enoxaparin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient20 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Acepromazine ,
                                                                                           :Acetaminophen ,
                                                                                           :Furosemide ,
                                                                                           :Lormetazepam ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report21
:Report21 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                     :Macrogol ,
                                                                                     :Salbutamol ,
                                                                                     :Tiotropium ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Budesonide/formoterol> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient21 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Bumetanide ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 21" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report22
:Report22 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                     :Cloxacillin ,
                                                                                     :Diltiazem ,
                                                                                     :Enoxaparin ,
                                                                                     :Rosuvastatin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient22 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Amoxicillin ,
                                                                                           :Levofloxacin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 22" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report23
:Report23 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Atorvastatin ,
                                                                                     :Clopidogrel ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient23 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 23" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report24
:Report24 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :RenalFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Dronedarone ,
                                                                                     :Fluindione ,
                                                                                     :Gliclazide ,
                                                                                     :Lercanidipine ,
                                                                                     :Perindopril ,
                                                                                     :Simvastatin ,
                                                                                     :Sotalol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient24 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Atorvastatin ,
                                                                                           :Gentamicin ,
                                                                                           :Spiramycin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 24" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report25
:Report25 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient25 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ciprofloxacin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 25" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report26
:Report26 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Alprazolam ,
                                                                                     :Enoxaparin ,
                                                                                     :Manidipine ,
                                                                                     :Milnacipran ,
                                                                                     :Pantoprazole ,
                                                                                     :Tramadol ,
                                                                                     :Valsartan ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient26 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 26" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report27
:Report27 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Amikacin ,
                                                                                     :Enoxaparin ,
                                                                                     :Pipobroman ,
                                                                                     :Pravastatin ,
                                                                                     :Pregabalin ,
                                                                                     :Propranolol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient27 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Acetaminophen ,
                                                                                           :Esomeprazole ,
                                                                                           :Heparin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 27" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report28
:Report28 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Digoxin ,
                                                                                     :Furosemide ,
                                                                                     :Paroxetine ,
                                                                                     :Ramipril ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient28 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 28" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report29
:Report29 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient29 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 29" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report30
:Report30 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient30 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 30" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report31
:Report31 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :Rash ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Bisoprolol ,
                                                                                     :Bromazepam ,
                                                                                     :Fluindione ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient31 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Amiodarone ,
                                                                                           :Furosemide ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 31" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report32
:Report32 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient32 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 32" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report33
:Report33 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient33 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ofloxacin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 33" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report34
:Report34 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Bromazepam ,
                                                                                     :Clopidogrel ,
                                                                                     :Enalapril ,
                                                                                     :Fluticasone ,
                                                                                     :Furosemide ,
                                                                                     :Hydrocortisone ,
                                                                                     :Omeprazole ,
                                                                                     :Tiotropium ,
                                                                                     :Tramadol ,
                                                                                     :Zolpidem ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient34 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 34" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report35
:Report35 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient35 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Fluindione ,
                                                                                           :Voriconazole ,
                                                                                           <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 35" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report36
:Report36 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :hyperbilirubinaemia ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient36 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ethambutol ,
                                                                                           :Isoniazid ,
                                                                                           :Levofloxacin ,
                                                                                           :Pyrazinamide ,
                                                                                           :Rifampicin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 36" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report37
:Report37 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acenocoumarol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient37 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 37" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report38
:Report38 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :Shock ,
                                                                                   :acuteRespiratoryDistressSyndrome ,
                                                                                   :liverFunctionTestsAbnormal ,
                                                                                   :sepsis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient38 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "irrelevant death" ;
          rdfs:label "Report 38" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report39
:Report39 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient39 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Acetaminophen ,
                                                                                           :Metoprolol ,
                                                                                           :Metronidazole ,
                                                                                           :Propofol ,
                                                                                           :Tramadol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 39" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetaminophen ,
                                                                                    :Colecalciferol ,
                                                                                    :Lactulose ,
                                                                                    :Lamotrigine ,
                                                                                    :Pantoprazole ,
                                                                                    :Valproic_Acid ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Clozapine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report40
:Report40 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient40 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Clindamycin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 40" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report41
:Report41 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient41 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 41" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report42
:Report42 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetylcysteine ,
                                                                                     :Furosemide ,
                                                                                     :Polygeline ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient42 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 42" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report43
:Report43 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :Neutropenia ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient43 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Levofloxacin ,
                                                                                           :Norfloxacin ,
                                                                                           :Ofloxacin ,
                                                                                           <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Colchicine/papaversomniferum/tiemonium> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 43" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report44
:Report44 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient44 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ciprofloxacin ,
                                                                                           <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 44" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report45
:Report45 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                     :Buflomedil ,
                                                                                     :Candesartan ,
                                                                                     :Pantoprazole ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient45 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Indapamide ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 45" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report46
:Report46 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :Jaundice ,
                                                                                   :Rash ,
                                                                                   :agranulocytosis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient46 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Moxifloxacin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 46" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report47
:Report47 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ALT_increased ,
                                                                                   :AST_increased ,
                                                                                   :HepaticEnzymesIncreased ,
                                                                                   :Hepatitis ,
                                                                                   :Jaundice ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient47 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 47" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report48
:Report48 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Simvastatin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient48 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 48" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report49
:Report49 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Amiodarone ,
                                                                                     :Buflomedil ,
                                                                                     :Nifedipine ,
                                                                                     :Sertraline ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient49 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Spiramycin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 49" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Valsartan ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ezetimibe ,
                                                                                          :Gliclazide ,
                                                                                          :Sitagliptin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report50
:Report50 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient50 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 50" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report51
:Report51 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :Nausea ,
                                                                                   :Vomitting ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Furosemide ,
                                                                                     :Gliclazide ,
                                                                                     :Omeprazole ,
                                                                                     :Ramipril ,
                                                                                     :methyldopa ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient51 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 51" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report52
:Report52 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Furosemide ,
                                                                                     :Omeprazole ,
                                                                                     :Tamoxifen ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient52 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Nefopam ,
                                                                                           :Ofloxacin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 52" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report53
:Report53 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :abdominalPain ,
                                                                                   :cholecystitis ,
                                                                                   :pyrexia ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient53 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 53" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report54
:Report54 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Flucloxacillin ,
                                                                                     :Gentamicin ,
                                                                                     :Indapamide ,
                                                                                     :Metronidazole ,
                                                                                     :Penicillin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient54 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 54" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report55
:Report55 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Amineptine ,
                                                                                     :Buflomedil ,
                                                                                     :Nitrendipine ,
                                                                                     :methyldopa ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient55 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ambroxol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 55" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report56
:Report56 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :pancreatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient56 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 56" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report57
:Report57 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Metopimazine ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient57 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Carbocisteine ,
                                                                                           :Formoterol ,
                                                                                           <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Phloroglucinol/trimethylphloroglucinol> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 57" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report58
:Report58 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :acuteKidneyInjury ,
                                                                                   :anuria ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient58 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 58" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report59
:Report59 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                     :Cyproterone ,
                                                                                     :Leuprorelin ,
                                                                                     :Nicergoline ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient59 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Metoclopramide ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 59" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Cholestasis ,
                                                                                  :Hepatitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Apixaban ,
                                                                                    :Bisoprolol ,
                                                                                    :Furosemide ,
                                                                                    :Levothyroxine ,
                                                                                    :Oxazepam ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Acetaminophen ,
                                                                                          :Ciprofloxacin ,
                                                                                          :Metronidazole ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report60
:Report60 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Amiodarone ,
                                                                                     :Digoxin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient60 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Dipyridamole ,
                                                                                           :Lorazepam ,
                                                                                           :Mianserin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 60" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report61
:Report61 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetaminophen ,
                                                                                     :Allopurinol ,
                                                                                     :Danazol ,
                                                                                     :Omeprazole ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient61 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ofloxacin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 61" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report62
:Report62 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatic_function_abnormal ,
                                                                                   :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient62 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 62" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report63
:Report63 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Enoxaparin ,
                                                                                     :Methylprednisolone ,
                                                                                     :Nifuroxazide ,
                                                                                     :Sucralfate ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient63 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 63" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report64
:Report64 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Labetalol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient64 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Cefuroxime ,
                                                                                           :Netilmicin ,
                                                                                           :Piroxicam ,
                                                                                           :Roxithromycin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 64" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report65
:Report65 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Clorazepic_acid ,
                                                                                     :Diltiazem ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient65 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 65" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report66
:Report66 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatic_function_abnormal ,
                                                                                   :Hepatitis ,
                                                                                   :circulatoryCollapse ,
                                                                                   :sepsis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient66 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 66" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report67
:Report67 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                   :boneMarrowFailure ,
                                                                                   :erythemaMultiforme ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient67 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Acetaminophen ,
                                                                                           <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 67" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report7
:Report7 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Cefotaxime ,
                                                                                          :Esomeprazole ,
                                                                                          <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#sulfamethoxazole/trimethoprim> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report8
:Report8 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ,
                                                                                  :Jaundice ,
                                                                                  :MetabolismDisorder ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Carbimazole ,
                                                                                          :Metronidazole ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Report9
:Report9 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Fluindione ,
                                                                                    :Potassium ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Bisoprolol ,
                                                                                          :Heparin ,
                                                                                          :Metronidazole ,
                                                                                          :Paroxetine ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsFroSouthKorea
:ReportsFroSouthKorea rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/South_Korea" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from South Korea" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsFromAustralia
:ReportsFromAustralia rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Australia" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from Australia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsFromFrance
:ReportsFromFrance rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 51 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/France" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                   rdfs:label "Reports from France" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsFromGermany
:ReportsFromGermany rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Germany" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Reports from Germany" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsFromItaly
:ReportsFromItaly rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Italy" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                  rdfs:label "Reports from Italy" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsFromSingapore
:ReportsFromSingapore rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Singapore" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from Singapore" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsFromSpain
:ReportsFromSpain rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Spain" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                  rdfs:label "Reports from Spain" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsFromUSA
:ReportsFromUSA rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_States" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                rdfs:label "Reports from USA" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsInWhichCeftriaxoneIsTheOnlySuspectDrug
:ReportsInWhichCeftriaxoneIsTheOnlySuspectDrug rdf:type owl:NamedIndividual ,
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 27 ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                               rdfs:label "Reports in which Ceftriaxone is the only suspect drug" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsOfHepaticFailureAndAssociatedDisorders
:ReportsOfHepaticFailureAndAssociatedDisorders rdf:type owl:NamedIndividual ,
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatic_failure_and_associated_disorders ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 20 ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                               rdfs:label "Reports for ceftriaxone and Hepatic failure and associated disorders" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsWithIntramuscularRouteOfAdministration
:ReportsWithIntramuscularRouteOfAdministration rdf:type owl:NamedIndividual ,
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :Intramuscular_administration ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 8 ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                               rdfs:label "Reports with intramuscular route of administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsWithIntravenousRouteOfAdministration
:ReportsWithIntravenousRouteOfAdministration rdf:type owl:NamedIndividual ,
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :Intravenous_administration ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 44 ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                             rdfs:label "Reports with intravenous route of administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsWithNoRecovery
:ReportsWithNoRecovery rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 7 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
                       rdfs:label "Reports with no recovery " .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsWithOralAdministration
:ReportsWithOralAdministration rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :Oral_administration ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Reports with oral administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsWithParenteralRouteOfAdministration
:ReportsWithParenteralRouteOfAdministration rdf:type owl:NamedIndividual ,
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :Parenterally_administration ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                            rdfs:label "Reports with parenteral route of administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsWithPositiveDechallenge
:ReportsWithPositiveDechallenge rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 50 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "positive - condition not applied" ;
                                rdfs:label "Reports with positive dechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsWithRecovery
:ReportsWithRecovery rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 52 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                     rdfs:label "Reports with  recovery " .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#ReportsWithSubcutaneousRouteOfAdministration
:ReportsWithSubcutaneousRouteOfAdministration rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :Subcutaneous_administration ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                              rdfs:label "Reports with subcutaneous route of administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Reports_in_Vigibase
:Reports_in_Vigibase rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A recent analysis by the UMC focussed on risk group identification looking at various covariates such as age, body mass index (BMI), gender and country. This found an association between ceftriaxone and hepatitis in patients aged 75 years and older. As of 7 October 2017, there are 67 ICSRs of hepatitis in association with ceftriaxone in patients 75 years and older in the VigiBase, the WHO global database of ICSRs. In the database as a whole, the association has an IC value of -0.16 with an IC025 value of -0.35. In the 75 years and older age group, however, the IC value is 0.86 with an IC025 value of 0.25. The cases were submitted from France (51 cases), Spain (5), Australia (4), the United States (3), Germany, Italy, Singapore and South Korea (all one each). The patients ranged in age from 75 to 94 years with a median of 84 years. The gender distribution was 21 males, 45 females and one not specified. Ceftriaxone was the only drug suspected in 27 of the 67 cases. In the remaining 40 cases, one other drug was suspected in 16 cases and from three to five other drugs suspected in 24 cases. Multiple suspected drugs include metronidazole, paracetamol, amoxicillin/clavulanic acid, ciprofloxacin, ofloxacin, levofloxacin, spiramycin, clozapine, esomeprazole, fluindione, furosemide, gentamicin, heparin, and indapamide. Concomitant drugs were reported in 37 cases, and together with 15 other cases in which there were multiple suspected drugs, there were only 15 reports in which ceftriaxone was the only drug reported to be used. The number of other drugs involved makes a detailed analysis difficult, but it does indicate a patient population with a significant level of morbidity. The indication for ceftriaxone was stated in 32 of the 67 reports and included urinary tract infection, bronchitis, other respiratory tract infections, other specified infections and unspecified infections. Dosage was indicated in 44 of the 67 reports and was most commonly one or two grams daily. The method of administration was reported in 57 of the 67 reports. This was by the intravenous route in 44 cases, the intramuscular route in 8 cases, and parenterally in one other case. The other four cases describe subcutaneous (two cases) and oral administration (two cases). Time to onset was reported in 59 of the 67 ICSRs. It ranged from 11 days before administration to 3 years after, but apart from these two outliers and one other case in which onset was before administration, the range was from the same day that administration began to about four months with a median of six days. However, in an unusual example of consistency in spontaneous reports, the onset in 53 cases ranged from the same day to 17 days. The outcome was stated in 59 reports. The patients were reported as recovered or recovering in 52 cases and not recovered in the remaining seven. In those where the outcome was reported as recovered or recovering, the drug was withdrawn in 50 cases, including eight cases in which the drug was stopped before onset and one case in which the drug was withdrawn long after recovery. In the two remaining cases, the drug was continued in one case and the action taken with the drug was unknown in the other case. In the cases where the patients had not recovered, the drug was withdrawn in six cases, including three cases in which the drug was withdrawn before onset, and the action taken with the drug was unknown in the remaining case. Other reactions were described in 18 of the reports. These included other hepatic reactions in nine cases including jaundice or cholestasis in five reports and increased levels of hepatic enzymes in five. Other reactions included skin reactions inWHO Pharmaceuticals Newsletter No. 6, 2018 • 26 Signal four cases, gastrointestinal reactions in three cases, haematological reactions in three cases, renal reactions in two cases and sepsis in two cases." ;
                     rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Reports_with_increased_levels_of_hepatic_enzymes
:Reports_with_increased_levels_of_hepatic_enzymes rdf:type owl:NamedIndividual ,
                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatic_enzymes_increased ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                  rdfs:label "Reports with increased levels of hepatic enzymes" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Reports_with_negative_dechallenge
:Reports_with_negative_dechallenge rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :ReportsWithNoRecovery ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 6 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dechallenge_outcome> "negative - condition still applied" ;
                                   rdfs:label "Reports with negative dechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Reports_with_sepsis
:Reports_with_sepsis rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :sepsis ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                     rdfs:label "Reports with sepsis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Rifampicin
:Rifampicin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J04AB02" ,
                                                                         "J04AM02" ,
                                                                         "J04AM05" ,
                                                                         "J04AM06" ;
            rdfs:label "Rifampicin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Rituximab
:Rituximab rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01XC02" ;
           rdfs:label "Rituximab" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Rosuvastatin
:Rosuvastatin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA07" ;
              rdfs:label "Rosuvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Rotigotine
:Rotigotine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N04BC09" ;
            rdfs:label "Rotigotine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Roxithromycin
:Roxithromycin rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01FA06" ;
               rdfs:label "Roxithromycin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Salbutamol
:Salbutamol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03CC02" ;
            rdfs:label "Salbutamol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Sertraline
:Sertraline rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AB06" ;
            rdfs:label "Sertraline" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Shock
:Shock rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R57" ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10040560 ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Shock" ;
       rdfs:label "Shock" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Simvastatin
:Simvastatin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BH51" ,
                                                                          "C10AA01" ,
                                                                          "C10BA02" ,
                                                                          "C10BA04" ,
                                                                          "C10BX01" ,
                                                                          "C10BX04" ;
             rdfs:label "Simvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Sitagliptin
:Sitagliptin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BD07" ,
                                                                          "A10BD12" ,
                                                                          "A10BH01" ,
                                                                          "A10BH51" ;
             rdfs:label "Sitagliptin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Sotalol
:Sotalol rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AA07" ;
         rdfs:label "Sotalol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Spiramycin
:Spiramycin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01FA02" ,
                                                                         "J01RA04" ;
            rdfs:label "Spiramycin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Statins
:Statins rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA" ;
         rdfs:label "Statins" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Subcutaneous_administration
:Subcutaneous_administration rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Intake_Form> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> "subcutaneous" ;
                             rdfs:label "Subcutaneous administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Sucralfate
:Sucralfate rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BX02" ;
            rdfs:label "Sucralfate" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Sulfadrugs
:Sulfadrugs rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01E" ;
            rdfs:label "Sulfa drugs" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Tamoxifen
:Tamoxifen rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L02BA01" ;
           rdfs:label "Tamoxifen" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Tetracyclines
:Tetracyclines rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01A" ;
               rdfs:label "Tetracyclines" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Thrombocytopenia
:Thrombocytopenia rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "D696" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10043554 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Thrombocytopenia" ;
                  rdfs:label "Thrombocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Time_to_onset
:Time_to_onset rdf:type owl:NamedIndividual ,
                        <http://www.w3.org/2006/time#DurationDescription> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Time to onset was reported in 59 of the 67 ICSRs. It ranged from 11 days before administration to 3 years after, but apart from these two outliers and one other case in which onset was before administration, the range was from the same day that administration began to about four months with a median of six days. However, in an unusual example of consistency in spontaneous reports, the onset in 53 cases ranged from the same day to 17 days." ;
               rdfs:label "Time to onset for ceftriaxone and hepatitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Tiotropium
:Tiotropium rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03BB04" ;
            rdfs:label "Tiotropium" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Total_IC025_value_for_Ceftriaxone_and_Hepatitis
:Total_IC025_value_for_Ceftriaxone_and_Hepatitis rdf:type owl:NamedIndividual ,
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_information_component> :Total_IC_value_for_Ceftriaxone_and_Hepatitis ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "07/10/2017"^^xsd:date ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> -0.35 ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 240 ;
                                                 rdfs:label "Total IC025 value for Ceftriaxone and Hepatitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Total_IC_value_for_Ceftriaxone_and_Hepatitis
:Total_IC_value_for_Ceftriaxone_and_Hepatitis rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "07/10/2017"^^xsd:date ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> -0.16 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 240 ;
                                              rdfs:label "Total IC value for Ceftriaxone and Hepatitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Tramadol
:Tramadol rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02AX02" ,
                                                                       "N02AX52" ;
          rdfs:label "Tramadol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Usage_of_ceftriaxone
:Usage_of_ceftriaxone rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Infections ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """It is used in the treatment of a large
variety of infections.""" ;
                      rdfs:label "Usage of ceftriaxone" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Valaciclovir
:Valaciclovir rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J05AB11" ;
              rdfs:label "Valaciclovir" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Valproic_Acid
:Valproic_Acid rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AG01" ;
               rdfs:label "Valproic Acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Valsartan
:Valsartan rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09CA03" ;
           rdfs:label "Valsartan" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Verapamil
:Verapamil rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08DA01" ;
           rdfs:label "Verapamil" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Vildagliptin
:Vildagliptin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BH02" ;
              rdfs:label "Vildagliptin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Vincristine
:Vincristine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01CA02" ;
             rdfs:label "Vincristine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Vomitting
:Vomitting rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R11. 10" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10047700 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Vomiting" ;
           rdfs:label "Vomiting" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Voriconazole
:Voriconazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J02AC03" ;
              rdfs:label "Voriconazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Zolpidem
:Zolpidem rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05CF02" ;
          rdfs:label "Zolpidem" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#abdominalPain
:abdominalPain rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R10" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10000081 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Abdominal pain" ;
               rdfs:label "abdominal pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#acuteKidneyInjury
:acuteKidneyInjury rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N17.9" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10069339 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Acute kidney injury" ;
                   rdfs:label "acute kidney injury" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#acuteRespiratoryDistressSyndrome
:acuteRespiratoryDistressSyndrome rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J80" ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10001052 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Acute respiratory distress syndrome" ;
                                  rdfs:label "acute respiratory distress syndrome" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#agranulocytosis
:agranulocytosis rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "D70" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10001507 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Agranulocytosis" ;
                 rdfs:label "agranulocytosis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#anuria
:anuria rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R34" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10002847 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Anuria" ;
        rdfs:label "anuria" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#boneMarrowFailure
:boneMarrowFailure rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "D61.89" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10065553 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Bone marrow failure" ;
                   rdfs:label "bone marrow failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#cholecystitis
:cholecystitis rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K81" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10008612 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cholecystitis" ;
               rdfs:label "cholecystitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#circulatoryCollapse
:circulatoryCollapse rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R579" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10009192 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Circulatory collapse" ;
                     rdfs:label "circulatory collapse" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#diarrhoea
:diarrhoea rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K591" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012735 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Diarrhoea" ;
           rdfs:label "diarrhoea" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#erythemaMultiforme
:erythemaMultiforme rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L51.9" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10015218 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Erythema multiforme" ;
                    rdfs:label "erythema multiforme" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#erythroblastocytopenia
:erythroblastocytopenia rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10049465 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Erythroblastopenia" ;
                        rdfs:label "erythroblastocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#fever
:fever rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R50" ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10016558 ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Fever" ;
       rdfs:label "fever" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#granulocytopenia
:granulocytopenia rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10018687 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Granulocytopenia" ;
                  rdfs:label "granulocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#haemolytic_anaemia
:haemolytic_anaemia rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10018916 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Haemolytic anaemia" ;
                    rdfs:label "haemolytic anaemia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#hepatotoxicity
:hepatotoxicity rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019851 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hepatotoxicity" ;
                rdfs:label "hepatotoxicity" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#hepatotoxicity_due_to_co-suspected_drugs
:hepatotoxicity_due_to_co-suspected_drugs rdf:type owl:NamedIndividual ,
                                                   <http://purl.obolibrary.org/obo/OAE_0001182> ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :hepatotoxicity ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ciprofloxacin ,
                                                                                                         :Levofloxacin ,
                                                                                                         :Metronidazole ,
                                                                                                         :Ofloxacin ,
                                                                                                         <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> ;
                                          mp:references :Ref.10 ,
                                                        :Ref.11 ,
                                                        :Ref.12 ,
                                                        :Ref.13 ,
                                                        :Ref.9 ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "However, of the suspected drugs which occur most in multiple cases, hepatotoxicity is mentioned as an adverse reaction in the product information for metronidazole, amoxicillin/clavulanic acid, ciprofloxacin, ofloxacin and levofloxacin, while hepatotoxicity is not mentioned as an adverse reaction in the product information for paracetamol (except in overdose).9-13" ;
                                          rdfs:label "hepatotoxicity due to co-suspected drugs" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#hyperbilirubinaemia
:hyperbilirubinaemia rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E807" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020578 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hyperbilirubinaemia" ;
                     rdfs:label "hyperbilirubinaemia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#introduction
:introduction rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction> ;
              mp:references :Ref.1 ,
                            :Ref.2 ,
                            :Ref.3 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Ceftriaxone is a cephalosporin antibiotic which inhibits bacterial cell wall synthesis following attachment to PBPs. This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death. It is used in the treatment of a large variety of infections. The most frequently reported adverse reactions for ceftriaxone are eosinophilia,WHO Pharmaceuticals Newsletter No. 6, 2018 • 25 Signal leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased.1 Hepatitis refers to an inflammatory condition of the liver. It’s commonly caused by a viral infection, but there are other possible causes of hepatitis including as a secondary result of medications, drugs, toxins, and alcohol. A large number of drugs have been implicated as a cause of hepatitis. These include paracetamol, non-steroidal antiinflammatory drugs (NSAIDs), amiodarone, anabolic steroids, oral contraceptives, chlorpromazine, erythromycin, halothane, methyldopa, isoniazid, methotrexate, statins, sulfa drugs, tetracyclines, amoxicillin-clavulanate and some anti-seizure medicines.2 Hepatitis is a preferred term in both WHO-ART and MedDRA, although in MedDRA there are many other related terms. As VigiLyze no longer supports WHO-ART, only MedDRA terms will be discussed in this assessment. The Council for International Organizations for Medical Sciences (CIOMS) recommends that in the absence of a histologically established diagnosis, the term liver injury is to be preferred to hepatocellular damage; the latter should be used only when there is pertinent histological evidence.3 Specific terms such hepatitis should be used only when the condition has been confirmed by histological or other means. It is, however, common practice for clinicians to use the term hepatitis. Liver injury (or hepatitis) can be further characterised as hepatocellular or cholestatic if the pertinent values of specific liver enzymes are available. Hepatocellular is defined when the ratio of the serum activity of alanine aminotransferase (ALT) expressed as a multiple of the upper limit of normal (ULN) divided by the serum activity of alkaline phosphatase (AP) expressed as a multiple of the ULN is greater than or equal to five. Cholestatic is defined when that ratio is less than two. The term mixed is used for values between two and five.3" ;
              rdfs:label "introduction" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#liverFunctionTestsAbnormal
:liverFunctionTestsAbnormal rdf:type owl:NamedIndividual ,
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10024690 ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Liver function test abnormal" ;
                            rdfs:label "liver function test abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#methyldopa
:methyldopa rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C02AB" ;
            rdfs:label "methyldopa" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#one_day_interval_between_administration
:one_day_interval_between_administration rdf:type owl:NamedIndividual ,
                                                  <http://www.w3.org/2006/time#DurationDescription> ;
                                         <http://www.w3.org/2006/time#days> 1 ;
                                         rdfs:label "one day interval between administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#pancreatitis
:pancreatitis rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K858" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10033645 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pancreatitis" ;
              rdfs:label "pancreatitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Signal> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> :Discussion_and_Conclusion ,
                                                                                      :Pathophysiology_of_hepatitis ,
                                                                                      :Reports_in_Vigibase ,
                                                                                      :introduction ,
                                                                                      :summary ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_individual_case_report> :Report1 ,
                                                                                                 :Report10 ,
                                                                                                 :Report11 ,
                                                                                                 :Report12 ,
                                                                                                 :Report13 ,
                                                                                                 :Report14 ,
                                                                                                 :Report15 ,
                                                                                                 :Report16 ,
                                                                                                 :Report17 ,
                                                                                                 :Report18 ,
                                                                                                 :Report19 ,
                                                                                                 :Report2 ,
                                                                                                 :Report20 ,
                                                                                                 :Report21 ,
                                                                                                 :Report22 ,
                                                                                                 :Report23 ,
                                                                                                 :Report24 ,
                                                                                                 :Report25 ,
                                                                                                 :Report26 ,
                                                                                                 :Report27 ,
                                                                                                 :Report28 ,
                                                                                                 :Report29 ,
                                                                                                 :Report3 ,
                                                                                                 :Report30 ,
                                                                                                 :Report31 ,
                                                                                                 :Report32 ,
                                                                                                 :Report33 ,
                                                                                                 :Report34 ,
                                                                                                 :Report35 ,
                                                                                                 :Report36 ,
                                                                                                 :Report37 ,
                                                                                                 :Report38 ,
                                                                                                 :Report39 ,
                                                                                                 :Report4 ,
                                                                                                 :Report40 ,
                                                                                                 :Report41 ,
                                                                                                 :Report42 ,
                                                                                                 :Report43 ,
                                                                                                 :Report44 ,
                                                                                                 :Report45 ,
                                                                                                 :Report46 ,
                                                                                                 :Report47 ,
                                                                                                 :Report48 ,
                                                                                                 :Report49 ,
                                                                                                 :Report5 ,
                                                                                                 :Report50 ,
                                                                                                 :Report51 ,
                                                                                                 :Report52 ,
                                                                                                 :Report53 ,
                                                                                                 :Report54 ,
                                                                                                 :Report55 ,
                                                                                                 :Report56 ,
                                                                                                 :Report57 ,
                                                                                                 :Report58 ,
                                                                                                 :Report59 ,
                                                                                                 :Report6 ,
                                                                                                 :Report60 ,
                                                                                                 :Report61 ,
                                                                                                 :Report62 ,
                                                                                                 :Report63 ,
                                                                                                 :Report64 ,
                                                                                                 :Report65 ,
                                                                                                 :Report66 ,
                                                                                                 :Report67 ,
                                                                                                 :Report7 ,
                                                                                                 :Report8 ,
                                                                                                 :Report9 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_statistical_entity> :IC025_value_for_Ceftriaxone_and_Hepatitis_above_75_years ,
                                                                                             :IC_value_for_Ceftriaxone_and_Hepatitis_above_75_years ,
                                                                                             :OverallReportsInVigibase ,
                                                                                             :ReportsFroSouthKorea ,
                                                                                             :ReportsFromAustralia ,
                                                                                             :ReportsFromFrance ,
                                                                                             :ReportsFromGermany ,
                                                                                             :ReportsFromItaly ,
                                                                                             :ReportsFromSingapore ,
                                                                                             :ReportsFromSpain ,
                                                                                             :ReportsFromUSA ,
                                                                                             :ReportsInWhichCeftriaxoneIsTheOnlySuspectDrug ,
                                                                                             :ReportsOfHepaticFailureAndAssociatedDisorders ,
                                                                                             :ReportsWithIntramuscularRouteOfAdministration ,
                                                                                             :ReportsWithIntravenousRouteOfAdministration ,
                                                                                             :ReportsWithNoRecovery ,
                                                                                             :ReportsWithOralAdministration ,
                                                                                             :ReportsWithParenteralRouteOfAdministration ,
                                                                                             :ReportsWithPositiveDechallenge ,
                                                                                             :ReportsWithRecovery ,
                                                                                             :ReportsWithSubcutaneousRouteOfAdministration ,
                                                                                             :Reports_with_increased_levels_of_hepatic_enzymes ,
                                                                                             :Reports_with_negative_dechallenge ,
                                                                                             :Reports_with_sepsis ,
                                                                                             :Total_IC025_value_for_Ceftriaxone_and_Hepatitis ,
                                                                                             :Total_IC_value_for_Ceftriaxone_and_Hepatitis ,
                                                                                             :reportsForCeftriaxoneAndCholestasis ,
                                                                                             :reportsForCeftriaxoneAndHepatitisCholestatic ,
                                                                                             :reportsForCeftriaxoneAndHepatocellularInjury ,
                                                                                             :reportsForCeftriaxoneAndJaundice ,
                                                                                             :reportsWithTimeToOnset ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Hepatitis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :Time_to_onset ;
          mp:supportedByData :Bell_report ,
                             :Ceftriaxone_labelling ,
                             :Frequently_reported_ADR_for_ceftriaxone ,
                             :Hepatotoxicity_and_penicillins-cephalosporins ,
                             :Literature_and_Labelling ,
                             :Longo_et_al__report ,
                             :Nadelman_report ,
                             :Peker_report ,
                             :hepatotoxicity_due_to_co-suspected_drugs ,
                             <http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Kaur/Singh_report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#initially_identified_on> "01/12/2018" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#pyrexia
:pyrexia rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R50.9" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037660 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pyrexia" ;
         rdfs:label "pyrexia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#reportsForCeftriaxoneAndCholestasis
:reportsForCeftriaxoneAndCholestasis rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Cholestasis ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 70 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                     rdfs:label "reports for ceftriaxone and cholestasis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#reportsForCeftriaxoneAndHepatitisCholestatic
:reportsForCeftriaxoneAndHepatitisCholestatic rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Cholestatic_hepatitis ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Ceftriaxone ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 21 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                              rdfs:label "reports for ceftriaxone and hepatitis cholestatic" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#reportsForCeftriaxoneAndHepatocellularInjury
:reportsForCeftriaxoneAndHepatocellularInjury rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :HepatocellularLiverInjury ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 33 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                              rdfs:label "reports for ceftriaxone and hepatocellular injury" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#reportsForCeftriaxoneAndJaundice
:reportsForCeftriaxoneAndJaundice rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Jaundice ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 26 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                  rdfs:label "reports for ceftriaxone and jaundice" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#reportsWithTimeToOnset
:reportsWithTimeToOnset rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :Time_to_onset ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 59 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                        rdfs:label "reports with time to onset" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#sepsis
:sepsis rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "A41" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10040047 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Sepsis" ;
        rdfs:label "sepsis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#summary
:summary rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Ceftriaxone is a cephalosporin antibiotic which inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). It is used in the treatment of a large variety of infections. The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased. In VigiBase, the WHO global database of individual case safety reports (ICSRs), there are currently (7 October 2017) 67 ICSRs of hepatitis in association with ceftriaxone in patients 75 years and older. The cases were submitted from Australia, France, Germany, Italy, Republic of Korea, Singapore, Spain and the United States. Ceftriaxone was the only drug suspected in 27 of these cases. Time to onset was reported in 59 of the 67 ICSRs, ranging from 11 days before administration to 3 years after, but apart from these two outliers and one other case in which onset was before administration, the range was from the same day that administration began to about four months with a median of six days. However, in an unusual example of consistency in spontaneous reports, the onset in 53 cases ranged from the same day to 17 days. The outcome was stated in 59 reports. The patients were reported as recovered or recovering in 52 cases and not recovered in the remaining seven reports. In the reports where the outcome was reported as recovered or recovering, the drug was withdrawn in 50 cases. The consistent time to onset and the cases reported as recovered or recovering after ceftriaxone withdrawal are highly suggestive of a drug-induced effect. In addition, the product information mentions raised liver enzymes and there are five reports of the association in the literature. In conclusion, although hepatitis may have other possible causes in some patients in this series, the use of ceftriaxone appears the most likely reason." ;
         rdfs:label "summary" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Benserazide_/_Levodopa
<http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Benserazide_/_Levodopa> rdf:type owl:NamedIndividual ,
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N04BA" ;
                                                                                               rdfs:label "Benserazide / Levodopa" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Budesonide/formoterol
<http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Budesonide/formoterol> rdf:type owl:NamedIndividual ,
                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03AK07" ;
                                                                                              rdfs:label "Budesonide / Formoterol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Colchicine/papaversomniferum/tiemonium
<http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Colchicine/papaversomniferum/tiemonium> rdf:type owl:NamedIndividual ,
                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A03AB17" ,
                                                                                                                                                                            "M04AC01" ,
                                                                                                                                                                            "N02A" ;
                                                                                                               rdfs:label "Colchicine / papaver somniferum / Tiemonium" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Kaur/Singh_report
<http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Kaur/Singh_report> rdf:type owl:NamedIndividual ,
                                                                                                   <http://purl.obolibrary.org/obo/OAE_0001197> ;
                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Cholestatic_hepatitis ;
                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Ceftriaxone ;
                                                                                          mp:references :Ref.8 ;
                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kaur and Singh reported the development of cholestatic hepatitis in a 24-year-old female patient a few days after the use of intravenous ceftriaxone. The patient recovered after three weeks.8" ;
                                                                                          rdfs:label "Kaur/Singh report" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Phloroglucinol/trimethylphloroglucinol
<http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#Phloroglucinol/trimethylphloroglucinol> rdf:type owl:NamedIndividual ,
                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A03AX12" ;
                                                                                                               rdfs:label "Phloroglucinol / trimethylphloroglucinol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid
<http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#amoxicillin/clavulanicacid> rdf:type owl:NamedIndividual ,
                                                                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01CR02" ;
                                                                                                   rdfs:label "amoxicillin / clavulanic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#sulfamethoxazole/trimethoprim
<http://purl.org/OpenPVSignal/Signals/2018_6_ceftriaxone_hepatitis.owl#sulfamethoxazole/trimethoprim> rdf:type owl:NamedIndividual ,
                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01EE01" ;
                                                                                                      rdfs:label "sulfamethoxazole / trimethoprim" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
